RPID on Nasdaq

RAPID MICRO BIOSYSTEMS, INC.

We are leading a global transformation toward fully automated microbial quality control ("MQC") within pharmaceutical manufacturing.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

$33.6MRevenue, fiscal 20252
-$47.1MNet income, fiscal 20252

Compare with EyePoint Pharmaceuticals, BioNano Genomics or Precipio, Inc., or pick any stock.

  • TickerRPID on Nasdaq1
  • IndustryLaboratory Analytical Instruments1
  • HeadquartersLexington, Massachusetts1
  • Incorporated inDE3
  • Business address25 Hartwell Avenue, Lexington, Ma 024213
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3

See how the biggest companies compare on our leaderboards

We are leading a global transformation toward fully automated microbial quality control ("MQC") within pharmaceutical manufacturing. Our products safeguard the most complex and critical bioprocessing workflows in the industry, enabling faster, safer, and higher capacity drug production. Through our unique expertise at the intersection of microbiology, robotic systems, and advanced vision algorithms, we are setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-141.1%Operating margin2
-140.3%Net margin2
19.7%Revenue growth, 20252
-141.9%Return on equity2
0.57×Debt to equity2
-$31.9MFree cash flow2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 70% of the revenue RAPID MICRO BIOSYSTEMS, INC. broke down this way in fiscal 2025.

  1. Product$23.4M270%up 25% from 2024
  2. Service$10.2M230%up 9% from 2024
Products and services by year
Products and services20242025
Product$18.7M$23.4M
Service$9.3M$10.2M

Regions

United States brought in 40% of the revenue RAPID MICRO BIOSYSTEMS, INC. broke down this way in fiscal 2025.

  1. United States$13.4M240%up 26% from 2024
  2. Switzerland$6.0M218%up 6% from 2024
  3. All Other Countries$5.8M217%down 13% from 2024
  4. DEMember$5.8M217%up 89% from 2024
  5. Japan$2.6M28%up 26% from 2024
Regions by year
Regions20242025
United States$10.6M$13.4M
Switzerland$5.7M$6.0M
All Other Countries$6.6M$5.8M
DEMember$3.0M$5.8M
Japan$2.1M$2.6M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development41¢$13.6M
  • Other costs59¢$19.9M
  • Income tax0¢$40.0K

Out of $33.6M in revenue.2 The company lost money this year.

Financial statements

Revenue56782$33.6M in 2025+109% since 2020
0$10.0M$20.0M$30.0M$40.0M2020: $16.1M$16.1M20202021: $23.2M$23.2M2021+45%2022: $17.1M$17.1M2022−26%2023: $22.5M$22.5M2023+31%2024: $28.1M$28.1M2024+25%2025: $33.6M$33.6M2025+20%
Operating income56782-$47.4M in 2025+55% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$30.5M-$30.5M20202021: -$47.2M-$47.2M2021+55%2022: -$63.2M-$63.2M2022+34%2023: -$56.6M-$56.6M2023−11%2024: -$49.9M-$49.9M2024−12%2025: -$47.4M-$47.4M2025−5%
Net income56782-$47.1M in 2025+27% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$37.1M-$37.1M20202021: -$73.5M-$73.5M2021+98%2022: -$60.8M-$60.8M2022−17%2023: -$52.5M-$52.5M2023−14%2024: -$46.9M-$46.9M2024−11%2025: -$47.1M-$47.1M2025+0%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2025-12-312024-12-31
Total revenue$33.6M$28.1M
Research and development$13.6M$14.6M
Sales and marketing$12.1M$13.3M
General and administrative$22.8M$21.9M
Total costs and operating expenses$81.0M$78.0M
Loss from operations-$47.4M-$49.9M
Interest income$1.5M$3.2M
Interest expense-$1.1M-$40.0K
Other expense, net-$110.0K-$112.0K
Total other income, net$309.0K$3.1M
Loss before income taxes-$47.1M-$46.9M
Income tax expense$40.0K$22.0K
Net loss-$47.1M-$46.9M
Net loss per share basic (in dollars per share)-$1.05-$1.08
Net loss per share diluted (in dollars per share)-$1.05-$1.08
Weighted average common shares outstanding - basic (in shares)44.7M shares43.6M shares
Weighted average common shares outstanding - diluted (in shares)44.7M shares43.6M shares

Compare RAPID MICRO BIOSYSTEMS, INC. with another company

Leadership

Who has led RAPID MICRO BIOSYSTEMS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Robert G. Spignesi Jr.2021–now

President

  1. Robert G. Spignesi Jr.2021–now

Chief financial officer

  1. Sean M. Wirtjes2021–now

Chief operating officer

  1. John J. Addington Wilson2021–now
2025
Board members and other officers (12)

Former names

  • RAPID MICRO BIOSYSTEMS INCOct 23, 2006 to Jul 15, 20093

Timeline

  1. Jul 14, 2021New chief executive Robert G. Spignesi Jr. becomes CEO13

Filings

264 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 44 major events, 123 insider forms, 24 large holders, 52 other. The latest 20:

  1. Aug 14, 2026SCHEDULE 13G/A EDGAR
  2. Aug 14, 2026SCHEDULE 13G EDGAR
  3. Aug 7, 202610-Q EDGAR
  4. Aug 7, 20268-K EDGAR
  5. Jul 24, 20264 EDGAR
  6. Jul 24, 20264 EDGAR
  7. Jul 8, 2026144 EDGAR
  8. Jul 1, 2026144 EDGAR
  9. Jun 22, 2026144 EDGAR
  10. Jun 10, 2026144 EDGAR
  11. Jun 2, 20264 EDGAR
  12. Jun 2, 20264 EDGAR
  13. Jun 2, 20264 EDGAR
  14. Jun 2, 20264 EDGAR
  15. Jun 2, 20264 EDGAR
  16. May 29, 2026SD EDGAR
  17. May 28, 20268-K EDGAR
  18. May 26, 20264 EDGAR
  19. May 26, 20264 EDGAR
  20. May 26, 20264 EDGAR

The 264 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

42 open-market trades by officers, directors and large owners since October 2021: 23 buys and 19 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 11, 2026Wilson John J. AddingtonCHIEF OPERATING OFFICERSale9,603$4.32$41.5KForm 4
Mar 11, 2026WIRTJES SEAN MCHIEF FINANCIAL OFFICERSale7,480$4.32$32.3KForm 4
Mar 10, 2026Spignesi Robert G. Jr.PRESIDENT AND CEOSale17,922$4.11$73.7KForm 4
Feb 20, 2026Wilson John J. AddingtonCHIEF OPERATING OFFICERSale5,403$3.92$21.2KForm 4
Feb 20, 2026WIRTJES SEAN MCHIEF FINANCIAL OFFICERSale17,254$3.92$67.6KForm 4
Feb 19, 2026Spignesi Robert G. Jr.PRESIDENT AND CEOSale38,327$3.89$149.1KForm 4
Feb 9, 2026Wilson John J. AddingtonCHIEF OPERATING OFFICERSale4,610$3.78$17.4KForm 4
Feb 9, 2026Spignesi Robert G. Jr.PRESIDENT AND CEOSale12,840$3.78$48.5KForm 4
Feb 9, 2026WIRTJES SEAN MCHIEF FINANCIAL OFFICERSale6,027$3.78$22.8KForm 4
Feb 4, 2026Longitude Venture Partners II, L.P.10% ownerSale49,000$3.88$190.1KForm 4
Feb 3, 2026Longitude Prime Partners, LLC10% ownerSale27,500$4.24$116.6KForm 4
Feb 2, 2026Longitude Prime Partners, LLC10% ownerSale27,500$4.25$116.9KForm 4
Jan 30, 2026Longitude Prime Partners, LLC10% ownerSale46,000$4.54$208.8KForm 4
Jan 23, 2026Longitude Prime Partners, LLC10% ownerSale7,739$4.06$31.4KForm 4
Jul 14, 2025Spignesi Robert G. Jr.PRESIDENT AND CEOSale11,881$3.32$39.4KForm 4
Jul 11, 2025Spignesi Robert G. Jr.PRESIDENT AND CEOSale11,874$3.33$39.5KForm 4
Jul 10, 2025Spignesi Robert G. Jr.PRESIDENT AND CEOSale11,617$3.40$39.5KForm 4
Jul 9, 2025Spignesi Robert G. Jr.PRESIDENT AND CEOSale11,247$3.51$39.5KForm 4
Jul 8, 2025Spignesi Robert G. Jr.PRESIDENT AND CEOSale10,824$3.51$38.0KForm 4
Dec 5, 2024PEI MELINDA LITHERLANDDirectorBuy9,120$1.04$9.5KForm 4

All 42 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 34. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Bain Capital Life Sciences Investors, LLC8,434,560$14.6M0.9%No change
Armistice Capital, LLC3,328,000$5.8M0.2%New
ABG-WTT Global Life Science Capital Partners GP Ltd1,848,296$3.2M37.4%No change
Vanguard Capital Management LLC982,034$1.7M0.0%−460
Evernest Financial Advisors, LLC506,000$875.4K0.2%+73,490
Advent International, L.P.379,794$657.0K0.0%−172,583
Essex Investment Management Co LLC362,696$627.5K0.1%−521,235
Millennium Management LLC236,599$409.3K0.0%−46,681
Geode Capital Management, LLC228,041$394.7K0.0%−19,136
Renaissance Technologies LLC212,101$366.9K0.0%+85,484
BlackRock, Inc.189,832$328.4K0.0%+32,600
Legato Capital Management LLC119,534$206.8K0.0%−155,390
Vanguard Fiduciary Trust Co110,484$191.1K0.0%+772
Dimensional Fund Advisors LP104,192$180.3K0.0%+16,603
State Street Corp93,874$162.4K0.0%No change
XTX Topco Ltd79,727$137.9K0.0%+18,657
Sei Investments Co66,869$115.7K0.0%−217,947
Northern Trust Corp42,106$72.8K0.0%−6,173
Algert Global LLC38,307$66.3K0.0%+15,126
Morgan Stanley27,587$47.7K0.0%−1,620
Jane Street Group, LLC25,931$44.9K0.0%−106,994
Citadel Advisors LLC16,142$27.9K0.0%New
Osaic Holdings, Inc.14,300$24.7K0.0%+300
Nano Cap New Millennium Growth Fund L P12,500$21.6K0.0%No change
American Century Companies Inc11,638$20.1K0.0%−5,284

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37